Skip to content
← Full study record

NCT01007942 · MORE INFO

Limitations, agreements, and source contact

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer · Source last updated 2017-04-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
All randomized patients were included in the FAS. Seven patients (4 in the everolimus arm \& 3 in the placebo arm) were randomized but never received treatment \& were therefore excluded from the Safety Set.
point Of Contact
email
trialandresults.registries@novartis.com
organization
Novartis Pharmaceuticals
phone
862-778-8300
title
Study Director
Complete source fields
certain Agreement
other Details
The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e.,data from all sites) in clinical trial or disclosure of trial results in their entirety.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
All randomized patients were included in the FAS. Seven patients (4 in the everolimus arm \& 3 in the placebo arm) were randomized but never received treatment \& were therefore excluded from the Safety Set.
point Of Contact
email
trialandresults.registries@novartis.com
organization
Novartis Pharmaceuticals
phone
862-778-8300
title
Study Director

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice